ArticleDrugs - real world outcomes2025

Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children's Hospital of Fudan University.

Xiaowen Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.